Skip to main content
Erschienen in: Reactions Weekly 1/2018

01.11.2018 | Case report

Adalimumab

Active tuberculosis: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat De Almeida Vianna PF, et al. The prevalence of latent and active tuberculosis in patients undergoing immunobiological therapy with tnf inhibitors in a tertiary care public hospital. Advances in Rheumatology 58 (Suppl. 1): 110-111 abstr. P477, 5-8 Sep 2018. Available from: URL: http://doi.org/10.1186/s42358-018-0019-7 [abstract] - Brazil De Almeida Vianna PF, et al. The prevalence of latent and active tuberculosis in patients undergoing immunobiological therapy with tnf inhibitors in a tertiary care public hospital. Advances in Rheumatology 58 (Suppl. 1): 110-111 abstr. P477, 5-8 Sep 2018. Available from: URL: http://​doi.​org/​10.​1186/​s42358-018-0019-7 [abstract] - Brazil
Metadaten
Titel
Adalimumab
Active tuberculosis: case report
Publikationsdatum
01.11.2018
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2018
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-018-54278-2

Weitere Artikel der Ausgabe 1/2018

Reactions Weekly 1/2018 Zur Ausgabe

Case report

Antibacterials

Case report

Crizotinib

Case report

Pembrolizumab